Biomx Inc Corporate Call Transcript
Good morning and welcome to the BiomX conference call to discuss results from the company's ongoing Phase 1b/2a trial in cystic fibrosis. (Operator Instructions)
I would now like to turn the call over to Marina Wolfson, Chief Financial Officer of BiomX. Please proceed.
Thank you for joining us today to discuss the results from Part 1 of our ongoing Phase 1b/2a trial evaluating BX004 for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis or CF.
Earlier today, BiomX issued a press release detailing results from Part 1 of our study and became available just after 6:30 AM Eastern Time and can be found on our website at biomx.com. A replay of this call will be available on the Investors section of our website.
Before we begin, I'd like to review the Safe Harbor provision. All statements on this call that are not factual historic statements may be deemed forward-looking statements.
For instance, we're using forward-looking statements when we discuss in the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |